ADMIRAL Trial: Adaptive Mediastinal Radiation With Chemo-Immunotherapy
Status:
Recruiting
Trial end date:
2026-11-30
Target enrollment:
Participant gender:
Summary
This phase II trial studies two questions in patients with stage III NSCLC: 1) does it
improve cancer control to add the drug Durvalumab, a type of immunotherapy, earlier in the
treatment course; and 2) by intensifying treatment with durvalumab, is it possible to avoid
mediastinal radiation to decrease side effects, without decreasing cancer control?